【摘要】 目的：探讨3HLZE/4HR方案优化治疗在慢性丙型肝炎合并肺结核患者中的应用效果。方法：选择2018年1月至2020年1月该院收治的慢性丙型肝炎合并肺结核患者80例作为研究对象，回顾性分析患者的临床资料，按照治疗方案的不同分为次序治疗组(A组)和联合治疗组(B组),每组40例。A组患者采用2HRZE/4HR标准方案治疗，B组患者采用3HLZE/4HR方案治疗。对比两组患者的疗程、治疗完成率、肝损伤发生率、耐药率及治疗总体费用。结果：B组患者的治疗完成率为97.50%(39/40),显著高于A组的85.00%(34/40);B组患者肝损伤发生率、耐药率分别为5.00%(2/40)、2.50%(1/40),显著低于A组的20.00%(8/40)、17.50%(7/40);B组患者的治疗总体费用为(2.05±0.43)万元，显著低于A组的(3.78±0.32)万元；B组患者的疗程为(7.13±2.05)个月，显著短于A组的(9.34±2.46)个月，上述差异均有统计学意义(P<0.05)。结论：2HRZE/4HR标准方案和3HLZE/4HR方案在慢性丙型肝炎合并肺结核患者的治疗中均有一定的应用价值，但3HLZE/4HR方案的疗效更佳，且能降低患者肝损伤发生率和耐药率。更多还原

【Abstract】 OBJECTIVE: To probe into the application effect of optimized treatment 3 HLZE/4 HR regimen on patients with chronic viral hepatitis C complicated with tuberculosis. METHODS: A total of 80 patients with chronic viral hepatitis C complicated with tuberculosis admitted into this hospital from Jan. 2018 to Jan. 2020 were selected as subjects, the clinical data was retrospectively analyzed, and the patients were divided into sequential treatment group(group A) and combined treatment group(group B) according to different treatment regimens, with 40 cases in each group. Group A was given standard 2 HRZE/4 HR regimen, and group B was given 3 HLZE/4 HR regimen. The course of treatment, treatment completion rate, incidence of liver injury, incidence of drug resistance and overall cost of treatment were compared between two groups. RESULTS: The treatment completion rate of group B was 97.50%(39/40), significantly higher than that of group A(85.00%, 34/40); the incidence of liver injury and drug resistance in group B were respectively 5.00%(2/40) and 2.50%(1/40), significantly lower than those of group A(20.00%, 8/40; 17.50%, 7/40); the overall cost of treatment in group B was(20.5±4.3) thousand yuan, significantly lower than(37.8±3.2) thousand yuan of group A; the course of treatment of group B was(7.13±2.05) months, significantly shorter than(9.34±2.46) months of group A, with statistically significant differences(P<0.05). CONCLUSIONS: Both the standard 2 HRZE/4 HR regimen and the 3 HLZE/4 HR regimen are valuable in the treatment of patients with chronic viral hepatitis C combined with tuberculosis, but the 3 HLZE/4 HR regimen has better therapeutic efficacy and can reduce the incidence of liver injury and drug resistance in patients.更多还原